open access
Deep molecular response on imatinib treatment — results from a real-life retrospective study
Affiliations- Departament of Clinical Oncology and Chemotherapy, Luxmed Onkology, Szmocka Hospital, Szamocka 6, 01-748 Warsaw, Poland
- Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
- Department of Hematology, Medical University of Lodz
open access
Abstract
Introduction: Tyrosine kinase inhibitors (TKIs) have dramatically changed the outcome of chronic myeloid leukemia (CML) patients. Recent research focused on TKI discontinuation after achieving a deep molecular response (DMR) has revealed that about half of the patients maintain the response. DMR is a key criterion for TKI discontinuation. Our retrospective, ‘real-life’ study was aimed at to estimating the proportion of patients treated with first-line imatinib (IM) who achieved DMR and thus may be candidates for discontinuation of TKI treatment in a real life setting.
Material and methods: Two hundred and twenty-three patients were enrolled. All patients started IM at 400 mg daily. The median age at the time of diagnosis was 57 years (range: 17–92).
Results: Eighty-five patients (43%) in the whole group achieved DMR. Early molecular response (EMR) was achieved by 136 (69%) patients and correlated with the DMR rate (53% with EMR vs 14% without, p < 0.001). Major molecular response (MMR) after a year of treatment was confirmed in 108 (55%) patients, and was predictive for achieving DMR at any time (69% with MMR vs. 24% without, p < 0.001).
Conclusion: DMR can be achieved in a significant proportion of patients in a real-life setting. We observed that both the achievement of an EMR at three months and MMR at 12 months were associated with a significant advantage in terms of DMR.
Abstract
Introduction: Tyrosine kinase inhibitors (TKIs) have dramatically changed the outcome of chronic myeloid leukemia (CML) patients. Recent research focused on TKI discontinuation after achieving a deep molecular response (DMR) has revealed that about half of the patients maintain the response. DMR is a key criterion for TKI discontinuation. Our retrospective, ‘real-life’ study was aimed at to estimating the proportion of patients treated with first-line imatinib (IM) who achieved DMR and thus may be candidates for discontinuation of TKI treatment in a real life setting.
Material and methods: Two hundred and twenty-three patients were enrolled. All patients started IM at 400 mg daily. The median age at the time of diagnosis was 57 years (range: 17–92).
Results: Eighty-five patients (43%) in the whole group achieved DMR. Early molecular response (EMR) was achieved by 136 (69%) patients and correlated with the DMR rate (53% with EMR vs 14% without, p < 0.001). Major molecular response (MMR) after a year of treatment was confirmed in 108 (55%) patients, and was predictive for achieving DMR at any time (69% with MMR vs. 24% without, p < 0.001).
Conclusion: DMR can be achieved in a significant proportion of patients in a real-life setting. We observed that both the achievement of an EMR at three months and MMR at 12 months were associated with a significant advantage in terms of DMR.
Keywords
chronic myeloid leukemia; imatinib; deep molecular response
About this articleTitle
Deep molecular response on imatinib treatment — results from a real-life retrospective study
Journal
Issue
Article type
Original research article
Pages
504-508
Published online
2021-04-28
Page views
4680
Article views/downloads
181
DOI
10.5603/AHP.a2021.0027
Bibliographic record
Acta Haematol Pol 2021;52(5):504-508.
Keywords
chronic myeloid leukemia
imatinib
deep molecular response
Authors
Aleksandra Gołos
Joanna Niesiobędzka-Krężel
Joanna Góra-Tybor
References (13)- Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29(5): 1123–1132.
- Hochhaus A, Larson R, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017; 376(10): 917–927.
- Jabbour E, Kantarjian HM, O'Brien S, et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol. 2011; 29(32): 4260–4265.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966–984.
- Jain P, Kantarjian H, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013; 121(24): 4867–4874.
- Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017; 35(3): 298–305.
- Saussele S, Richter J, Guilhot J, et al. EURO-SKI investigators. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018; 19(6): 747–757.
- Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016; 128(1): 17–23.
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013; 122(6): 872–884.
- Nicolini FE, Alcazer V, Cony-Makhoul P, et al. Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib. Exp Hematol. 2018; 64: 97–105.e4.
- Castagnetti F, Di Raimondo F, De Vivo A, et al. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. Am J Hematol. 2017; 92(1): 82–87.
- Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3): 232–238.
- Molica M, Colafigli G, Scalzulli E, et al. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. Ann Hematol. 2019; 98(8): 1891–1904.